Supplementary file 8_Global burden of pancreatitis among individuals aged 15–39 years: a systematic analysis from the 2021 GBD study.docx by Biwu Xu (21431858)

“…Background<p>Pancreatitis represents a significant global public health challenge, yet there is a lack of comprehensive analyses focusing on the burden of pancreatitis and its long-term trends among young individuals aged 15–39 years.…”

Additional file 1 of Genome-wide association study of agronomic traits in winter wheat (Triticum aestivum L.) using a custom SNP marker set by Mikhail Bazhenov (22354266)

“…Additional file 9.xlsx Significant marker-trait associations.…”

Supplementary file 7_Global burden of pancreatitis among individuals aged 15–39 years: a systematic analysis from the 2021 GBD study.docx by Biwu Xu (21431858)

“…Background<p>Pancreatitis represents a significant global public health challenge, yet there is a lack of comprehensive analyses focusing on the burden of pancreatitis and its long-term trends among young individuals aged 15–39 years.…”

Supplementary file 6_Global burden of pancreatitis among individuals aged 15–39 years: a systematic analysis from the 2021 GBD study.docx by Biwu Xu (21431858)

“…Background<p>Pancreatitis represents a significant global public health challenge, yet there is a lack of comprehensive analyses focusing on the burden of pancreatitis and its long-term trends among young individuals aged 15–39 years.…”

Image 1_Double-lumen tubes verus single-lumen tube in patients undergoing minimally invasive cardiac surgery: a randomised, controlled clinical trial.pdf by Zhenzhong Wang (407028)

“…The PaO₂/FiO₂ were significantly greater in the SLT group than in the DLT group (P < 0.001). …”

Table 1_Immune checkpoint proteins are associated with persistently high liver stiffness after successful HCV treatment in people with HIV: a retrospective study.docx by Rubén Martín-Escolano (17411991)

“…Although LSM values showed a decreasing trend over the years following successful HCV treatment, this trend was not statistically significant due to substantial variability among PWH. …”

Data Sheet 1_Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial.pdf by Li-qin Meng (20633030)

“…</p>Results<p>Following treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P = 0.013) and a reduction in the frequency of angina episodes (P = 0.021). …”

Alternative representation of daunorubicin fluorescence testing of novel inhibitors. by Lauren A. McCormick (20540638)

“…Note that for compound 78, the significance denotes a significant decrease in fluorescence.…”

Supplementary file 1_Effect of Bifidobacterium longum subsp. infantis YLGB-1496 on common diseases in pediatrics: a randomized, blinded, placebo-controlled trial.docx by Xi Zhang (83736)

“…</p>Conclusion<p>Daily administration of YLGB-1496 at a dosage of 1.5 × 10¹⁰ CFU for 3 months significantly reduced the episodes of cough, fever, dry stool (defined as Bristol stool scale type 1–3), and eczematous changes of the skin. …”

Table1_Berberine alleviates ETEC-induced intestinal inflammation and oxidative stress damage by optimizing intestinal microbial composition in a weaned piglet model.docx by Yue Wang (65477)

“…A correlation analysis showed that berberine significantly increased the relative abundance of beneficial bacteria (Gemmiger, Pediococcus, Levilactobacillus, Clostridium, Lactiplantibacillus, Weissella, Enterococcus, Blautia, and Butyricicoccus) and decreased that of pathogenic bacteria (Prevotella, Streptococcus, Parabacteroides, Flavonifractor, Alloprevotella) known to be closely related to intestinal inflammation and oxidative stress in piglets. …”

Data Sheet 1_The relationship between intrinsic capacity and sarcopenia in middle-aged and older Chinese populations: the mediating influence of a novel nutritional index.zip by Hong Ding (135247)

“…Higher TCBI was associated with a 28% decrease in sarcopenia risk per unit increase (OR = 0.72, 95% CI: 0.58–0.90, p = 0.004). …”

Parameters of Tissue Doppler Echocardiography. by Mina Farshidgohar (20308230)

“…</p><p>Results</p><p>Out of 50 patients, two showed a decrease in left ventricular ejection fraction (LVEF) below the normal range (<55%) one month post-treatment, along with significant increases in Troponin I levels. …”

Table 1_Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial.docx by Hiroo Fukada (5154824)

“…The dapagliflozin group showed additional benefits, with significant decreases in BMI and HbA1c, γ-GT, ferritin, LDL cholesterol, and body fat levels, indicating improved glycemic control and lipid profile. …”

Baseline characteristics of patients. by Su Hwan Park (15158181)

“…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …”

Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Table 1_Long-term multicomponent exercise enhances functional mobility in early-stage Parkinson’s disease: a 48-month retrospective cohort study.docx by Marcos Moura (22671914)

“…Minimal detectable change (MDC), effect sizes, and linear regressions were computed.</p>Results<p>After 48 months, TUG time decreased by −3.8 s (95% CI: −5.0 to −2.6; p < 0.001; dz = −1.12) and 6MWT distance increased by +88.8 m (95% CI: 45.1 to 133.0; p < 0.001; dz = 0.72), both exceeding MDC thresholds. …”

Table 1_Associations between systemic inflammatory indices and the risk of renal function decline in patients with type 2 diabetes mellitus: a retrospective cohort study.docx by Zhi Shang (4849129)

“…The RCS analysis suggested a non-linear association of systemic inflammatory indices with the risk of renal function decline (P for nonlinear < 0.001). …”